Answers are grounded in this paper and cite their sources.
Low ALC at the time of CMV treatment completion was a strong independent predictor for recurrent CMV disease. This finding is biologically plausible given the known importance of T-cell immunity in maintaining CMV latency. Future studies should consider this inexpensive, readily available marker of host immunity.
No takes yet. Share an insight, caveat, or question.
Gardiner et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: